Brief: Syros Pharmaceuticals Inc Expects To Complete Enrollment In Select-Mds-1 Late-stage Study In 4Q 2023

Syros Pharmaceuticals

09/01/2023 13:46

Jan 9 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS PHARMACEUTICALS INC - EXPECT TO COMPLETE ENROLLMENT
IN
SELECT-MDS-1 PHASE 3 TRIAL IN 4Q 2023; DATA EXPECTED IN 3Q 2024
    * SYROS PHARMACEUTICALS INC - ENTERING 2023 IN STRONG
FINANCIAL
POSITION, WITH CASH INTO 2Q 2025
    * SYROS PHARMACEUTICALS INC - ON TRACK TO INITIATE
RANDOMIZED
PORTION OF SELECT-AML-1 PHASE 2 TRIAL IN 1Q 2023; INITIAL DATA
EXPECTED 4Q 2023

Source text for Eikon:  ID:nBw4r1vBma 
Further company coverage:  SYRS.O 
 ((Reuters.Briefs@thomsonreuters.com;))